

## **FURTHER INFORMATION ON SHAREHOLDERS' RIGHTS UNDER SECTIONS 109, 110, 118 AND 119 AktG AND INFORMATION ON SHAREHOLDERS' DATA PROTECTION**

### **Additions to the agenda by shareholders pursuant to Sec. 109 Austrian Stock Corporation Act (AktG)**

**Shareholders** whose shares individually or collectively amount to **5% of the share capital** and who have held these shares for at least three months prior to submitting their request may request in writing that **additional items** be placed **on the agenda** of this General Meeting and published, provided that this request is received by the Company in writing by post or courier by **4 September 2025** (midnight Vienna time) at the latest, exclusively at the address **Marinomed Biotech AG, attn. Bernd Braunstein, Hovengasse 25, 2100 Korneuburg, Austria**. Each agenda item so requested must be accompanied by a proposed resolution and a statement of reasons. The agenda item and the proposed resolution, but not the reasons for it, must also be submitted in German language. Proof of shareholder status must be provided by submitting a certificate of deposit in accordance with Sec. 10a Austrian Stock Corporation Act (AktG), which confirms that the shareholder(s) submitting the motion have held the shares for at least three months prior to submitting the motion and which must not be older than seven days at the time of submission to the Company. Several deposit confirmations for shares that only together represent the 5% shareholding must refer to the same date (day, time). With regard to the other requirements for the certificate of deposit, please refer to the information on the right to participate in the General Meeting, as provided in the convocation (point III.).

### **Proposed resolutions by shareholders pursuant to Sec. 110 Austrian Stock Corporation Act (AktG)**

Shareholders whose shares individually or collectively amount to **1% of the share capital** may submit **proposals for resolutions** on any item on the agenda of this General Meeting in text form within the meaning of Sec. 13 Para. 2 Austrian Stock Corporation Act (AktG) and request that these proposals be made available on the Company's website together with the names of the shareholder(s) concerned, the reasons to be attached and any statement by the Management Board or Supervisory Board. It should be noted that each proposed resolution must be accompanied by a statement of reasons. Such a request is only valid if it is received by the Company at the address **Marinomed Biotech AG, attn. Bernd Braunstein, Hovengasse 25, 2100 Korneuburg, Austria**, or by e-mail: [ir@marinomed.com](mailto:ir@marinomed.com) by **12 September 2025** (24:00 Vienna time) at the latest, whereby the request must be in text form within the meaning of Sec. 13 Para. 2 Austrian Stock Corporation Act (AktG), for example as a .pdf-file attached to the e-mail. If text form within the meaning of Sec. 13 Para. 2 Austrian Stock Corporation Act (AktG) is required for declarations, the declaration must be made in a document or in another manner suitable for permanent reproduction in writing, the person making the declaration must be named and the conclusion of the declaration must be made recognizable by reproducing the name signature or otherwise. The proposed resolution, but not the reasons for it, must also be submitted in German language.

### **Note on the right to information pursuant to Sec. 118 Austrian Stock Corporation Act (AktG)**

Upon request, each shareholder must be provided with information on the company's affairs at the General Meeting, insofar as this is necessary for the proper assessment of an item on the agenda. The obligation to provide information also extends to the company's legal and business relationships with an affiliated company. If the consolidated financial statements and the group management report are presented at the General Meeting of a parent company (Sec. 189a

Para. 6 in conjunction with Sec. 244 Austrian Company Code (UGB)), the obligation to provide information also extends to the situation of the group and the companies included in the consolidated financial statements.

The information must comply with the principles of conscientious and faithful accountability. The information must be provided at the General Meeting.

Information may be refused if

1. according to reasonable business judgment, it is likely to cause a significant disadvantage to the company or an affiliated company, or
2. their issuance would be punishable by law.

Every shareholder who attends the General Meeting is entitled to information. The right to information applies not only to the shareholder himself, but also to his legal or authorized representative.

Questions that require longer preparation to answer should be submitted to the Management Board in text form in good time before the General Meeting to ensure that the meeting is held efficiently. The questions can be sent to the Company by email to [ir@marinomed.com](mailto:ir@marinomed.com).

#### **Information on the right of shareholders to submit motions at the General Meeting pursuant to Sec. 119 Austrian Stock Corporation Act (AktG)**

Every shareholder – irrespective of a specific shareholding – is entitled to submit motions at the General Meeting on any item on the agenda (exception: proposed resolutions for election to the Supervisory Board). The prerequisite for this is proof of the right to participate as defined in the convocation. The right to submit motions is not only granted to shareholders themselves, but also to their legal or authorized representative(s) attending the General Meeting.

#### **Information on the protection of shareholders' data**

Marinomed Biotech AG processes shareholders' **personal data** (in particular those pursuant to Sec. 10a (2) Austrian Stock Corporation Act (AktG), i.e. name, address, date of birth, securities account number, number of shares held by the shareholder, class of shares if applicable, voting card number and, if applicable, name and date of birth of the proxy or proxies) on the basis of the applicable data protection regulations, in particular the **European General Data Protection Regulation (GDPR)** and the Austrian **Data Protection Act**, in order to enable shareholders to exercise their rights at the General Meeting.

The processing of shareholders' personal data is mandatory for the participation of shareholders and their representatives in the General Meeting in accordance with the Austrian Stock Corporation Act (AktG). The legal basis for the processing is therefore **Art. 6 (1) c) GDPR**.

Marinomed Biotech AG is the **controller responsible** for the processing. Marinomed Biotech AG uses external **service providers**, such as notaries, lawyers, banks and IT service providers, for the purpose of organizing the General Meeting. These companies only receive personal data from Marinomed Biotech AG that is necessary for the execution of the commissioned service and process the data exclusively in accordance with the instructions of Marinomed Biotech AG. Where legally required, Marinomed Biotech AG has concluded **data protection agreements** with these service providers.

If a shareholder participates in the General Meeting, all shareholders present or their representatives, the members of the Management Board and Supervisory Board, the notary and all other persons with a legal right to participate may inspect the legally required **list of participants** (Sec. 117 Austrian Stock Corporation Act (AktG)) and thereby also inspect the

personal data specified therein (including name, place of residence, shareholding). Marinomed Biotech AG is legally obliged to submit personal shareholder data (in particular the list of participants) as part of the notarial record to the **commercial register** (Sec. 120 Austrian Stock Corporation Act (AktG)).

The shareholders' data is anonymized or deleted as soon as it is no longer required for the purposes for which it was collected or processed and unless other legal obligations require further storage. **Obligations of proof and retention** arise in particular from company, stock corporation and takeover law, from tax and duty law and from money laundering regulations. If legal claims are asserted by shareholders against Marinomed Biotech AG or vice versa by Marinomed Biotech AG against shareholders, the storage of personal data serves to **clarify and enforce claims** in individual cases. In connection with legal proceedings before civil courts, this may lead to the storage of data for the duration of the limitation period plus the duration of the legal proceedings until their legally binding conclusion.

Every shareholder has a right **of access, rectification, restriction, objection and erasure** regarding the processing of personal data at any time, as well as a **right to data portability** in accordance with Chapter III of the GDPR. Shareholders can assert these rights against Marinomed Biotech AG free of charge via the e-mail address [office@marinomed.com](mailto:office@marinomed.com) or via the following **contact details**

Marinomed Biotech AG  
Attn. Andreas Grassauer  
Hovengasse 25  
2100 Korneuburg  
Austria

Shareholders also have **the right to lodge a complaint** with the **data protection supervisory authority** in accordance with Article 77 GDPR.

Note:

*This is a working translation of the German language version and for convenience only. In the event of conflict with the German language version, the German language version shall prevail.*